Literature DB >> 12901890

Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers.

Gavin D Barlow1, Donna L Lamping, Peter G Davey, Dilip Nathwani.   

Abstract

Community-acquired pneumonia (CAP) is a key target for research and quality improvement in acute medicine. However, many of the outcome measures used in prognostic and antibiotic studies are not validated and do not capture features of outcome that are important to patients. Substitutes for traditional outcome measures include a recently validated patient-based symptom questionnaire (the CAP-Sym) and process-of-care measures. The interpretation of outcomes also depends on the quality of the study design and methods used. This paper discusses the advantages and disadvantages of outcome, process-of-care, and economic measures in CAP and the interpretation of these measures in randomised and observational studies. A core set of measures for use in clinical CAP research and performance measurement is proposed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901890     DOI: 10.1016/s1473-3099(03)00721-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  13 in total

1.  Poor clinical outcomes among pneumonia patients with schizophrenia.

Authors:  Yi-Hua Chen; Hsiu-Chen Lin; Herng-Ching Lin
Journal:  Schizophr Bull       Date:  2010-03-25       Impact factor: 9.306

2.  Community-acquired pneumonia: doctors do not follow national guidelines.

Authors:  Paul Collini; Mike Beadsworth; Jim Anson; Tim Neal; Peter Burnham; Paul Deegan; Nick Beeching; Alastair Miller
Journal:  Postgrad Med J       Date:  2007-08       Impact factor: 2.401

Review 3.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

4.  Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.

Authors:  J Pradelli; K Risso; F G de Salvador; E Cua; R Ruimy; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-02       Impact factor: 3.267

Review 5.  Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients.

Authors:  Jesús López-Alcalde; Ricardo Rodriguez-Barrientos; Jesús Redondo-Sánchez; Javier Muñoz-Gutiérrez; José María Molero García; Carmen Rodríguez-Fernández; Julio Heras-Mosteiro; Jaime Marin-Cañada; Jose Casanova-Colominas; Amaya Azcoaga-Lorenzo; Virginia Hernandez Santiago; Manuel Gómez-García
Journal:  Cochrane Database Syst Rev       Date:  2018-09-06

6.  Poor clinical outcomes among pneumonia patients with depressive disorder.

Authors:  Li-Ting Kao; Shih-Ping Liu; Herng-Ching Lin; Hsin-Chien Lee; Ming-Chieh Tsai; Shiu-Dong Chung
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

7.  Psoriasis and the risk of pneumonia: a population-based study.

Authors:  Li-Ting Kao; Cha-Ze Lee; Shih-Ping Liu; Ming-Chieh Tsai; Herng-Ching Lin
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

8.  A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days.

Authors:  Daniel G Wootton; Laura Dickinson; Henry Pertinez; Joanne Court; Odiri Eneje; Lynne Keogan; Laura Macfarlane; Sarah Wilks; Jane Gallagher; Mark Woodhead; Stephen B Gordon; Peter J Diggle
Journal:  Eur Respir J       Date:  2017-06-15       Impact factor: 16.671

9.  Patient-reported outcome measures in community-acquired pneumonia: a systematic review of application and content validity.

Authors:  Melanie Lloyd; Emily Callander; Amalia Karahalios; Lucy Desmond; Harin Karunajeewa
Journal:  BMJ Open Respir Res       Date:  2019-06-02

10.  Improving management of patients with acute cough by C-reactive protein point of care testing and communication training (IMPAC3T): study protocol of a cluster randomised controlled trial.

Authors:  Jochen W L Cals; Rogier M Hopstaken; Christopher C Butler; Kerenza Hood; Johan L Severens; Geert-Jan Dinant
Journal:  BMC Fam Pract       Date:  2007-03-29       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.